WO2007068485A3 - Biological materials and uses thereof - Google Patents

Biological materials and uses thereof Download PDF

Info

Publication number
WO2007068485A3
WO2007068485A3 PCT/EP2006/012065 EP2006012065W WO2007068485A3 WO 2007068485 A3 WO2007068485 A3 WO 2007068485A3 EP 2006012065 W EP2006012065 W EP 2006012065W WO 2007068485 A3 WO2007068485 A3 WO 2007068485A3
Authority
WO
WIPO (PCT)
Prior art keywords
biological materials
surface antigen
binding
cell surface
target cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/012065
Other languages
French (fr)
Other versions
WO2007068485A2 (en
Inventor
Bjoern Frendeus
Roland Carlsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bioinvent International AB
Original Assignee
Bioinvent International AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to UAA200809108A priority Critical patent/UA100664C2/en
Priority to AU2006326267A priority patent/AU2006326267B2/en
Priority to SI200632069A priority patent/SI1960432T1/en
Priority to ES06829616.9T priority patent/ES2577290T3/en
Priority to EP06829616.9A priority patent/EP1960432B1/en
Priority to BRPI0619741-8A priority patent/BRPI0619741A2/en
Priority to US12/097,193 priority patent/US7943744B2/en
Priority to KR1020147003908A priority patent/KR20140031402A/en
Priority to RU2008128471/10A priority patent/RU2432363C9/en
Priority to CA2632983A priority patent/CA2632983C/en
Priority to KR1020087014064A priority patent/KR101446508B1/en
Priority to HK09101300.4A priority patent/HK1121767B/en
Application filed by Bioinvent International AB filed Critical Bioinvent International AB
Priority to JP2008544879A priority patent/JP5247463B2/en
Priority to KR20157002482A priority patent/KR20150023914A/en
Priority to DK06829616.9T priority patent/DK1960432T3/en
Priority to CN2006800512130A priority patent/CN101360760B/en
Priority to NZ569038A priority patent/NZ569038A/en
Publication of WO2007068485A2 publication Critical patent/WO2007068485A2/en
Publication of WO2007068485A3 publication Critical patent/WO2007068485A3/en
Priority to IL191868A priority patent/IL191868A/en
Priority to NO20082524A priority patent/NO341192B1/en
Anticipated expiration legal-status Critical
Priority to US13/053,846 priority patent/US8758749B2/en
Priority to US14/250,898 priority patent/US9803013B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2821—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against ICAM molecules, e.g. CD50, CD54, CD102
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The invention provides binding molecules, including antibody molecules which selectively bind to a cell surface antigen of a target cell, and wherein the binding molecules, on binding the cell surface antigen, induce apoptosis of the target cell. There is also provided methods of and pharmaceutical compositions for apoptosis induction and uses thereof.
PCT/EP2006/012065 2005-12-12 2006-12-08 Biological materials and uses thereof Ceased WO2007068485A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
UAA200809108A UA100664C2 (en) 2005-12-12 2006-08-12 Method for inducing apoptosis in a target cell
JP2008544879A JP5247463B2 (en) 2005-12-12 2006-12-08 Biological materials and their use
ES06829616.9T ES2577290T3 (en) 2005-12-12 2006-12-08 Apoptosis inducing anti-ICAM antibody
EP06829616.9A EP1960432B1 (en) 2005-12-12 2006-12-08 Anti-ICAM antibody inducing apoptosis.
BRPI0619741-8A BRPI0619741A2 (en) 2005-12-12 2006-12-08 method for inducing apoptosis in a target cell, binding molecule, nucleic acid antibody molecule, use of a binding molecule or antibody molecule, and, pharmaceutical composition
US12/097,193 US7943744B2 (en) 2005-12-12 2006-12-08 ICAM-1 binding antibodies
KR1020147003908A KR20140031402A (en) 2005-12-12 2006-12-08 Biological materials and uses thereof
RU2008128471/10A RU2432363C9 (en) 2005-12-12 2006-12-08 Biological materials and application thereof
CA2632983A CA2632983C (en) 2005-12-12 2006-12-08 Anti-icam1 antibodies for inducing apoptosis
SI200632069A SI1960432T1 (en) 2005-12-12 2006-12-08 Anti-ICAM antibody inducing apoptosis.
HK09101300.4A HK1121767B (en) 2005-12-12 2006-12-08 Anti-icam antibody inducing apoptosis
AU2006326267A AU2006326267B2 (en) 2005-12-12 2006-12-08 Biological materials and uses thereof
DK06829616.9T DK1960432T3 (en) 2005-12-12 2006-12-08 Anti-ICAM-antistof der inducerer apoptose
KR1020087014064A KR101446508B1 (en) 2005-12-12 2006-12-08 Biological materials and their uses
KR20157002482A KR20150023914A (en) 2005-12-12 2006-12-08 Biological materials and uses thereof
CN2006800512130A CN101360760B (en) 2005-12-12 2006-12-08 Biomaterials and their uses
NZ569038A NZ569038A (en) 2005-12-12 2006-12-08 Methods for inducing apoptosis in a target cell using anti-icam-1 anti bodies
IL191868A IL191868A (en) 2005-12-12 2008-06-01 In vitro method of inducing apoptosis in a target cell
NO20082524A NO341192B1 (en) 2005-12-12 2008-06-02 Apoptosis-inducing anti-ICAM antibody
US13/053,846 US8758749B2 (en) 2005-12-12 2011-03-22 Biological materials and uses thereof
US14/250,898 US9803013B2 (en) 2005-12-12 2014-04-11 Biological materials and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0525214A GB0525214D0 (en) 2005-12-12 2005-12-12 Biological materials and uses thereof
GB0525214.3 2005-12-12

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/097,193 A-371-Of-International US7943744B2 (en) 2005-12-12 2006-12-08 ICAM-1 binding antibodies
US13/053,846 Continuation US8758749B2 (en) 2005-12-12 2011-03-22 Biological materials and uses thereof

Publications (2)

Publication Number Publication Date
WO2007068485A2 WO2007068485A2 (en) 2007-06-21
WO2007068485A3 true WO2007068485A3 (en) 2007-10-04

Family

ID=35735917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/012065 Ceased WO2007068485A2 (en) 2005-12-12 2006-12-08 Biological materials and uses thereof

Country Status (23)

Country Link
US (3) US7943744B2 (en)
EP (2) EP2468775A1 (en)
JP (3) JP5247463B2 (en)
KR (3) KR20150023914A (en)
CN (2) CN101360760B (en)
AU (1) AU2006326267B2 (en)
BR (1) BRPI0619741A2 (en)
CA (1) CA2632983C (en)
DK (1) DK1960432T3 (en)
ES (1) ES2577290T3 (en)
GB (1) GB0525214D0 (en)
HU (1) HUE028363T2 (en)
IL (1) IL191868A (en)
MY (1) MY147438A (en)
NO (1) NO341192B1 (en)
NZ (2) NZ595644A (en)
PL (1) PL1960432T3 (en)
PT (1) PT1960432T (en)
RU (1) RU2432363C9 (en)
SI (1) SI1960432T1 (en)
UA (1) UA100664C2 (en)
WO (1) WO2007068485A2 (en)
ZA (1) ZA200804864B (en)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0525214D0 (en) 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
US20100041874A1 (en) * 2006-10-03 2010-02-18 Genmab A/S High throughput methods for characterization of antibodies
GB0903151D0 (en) * 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods
EP2493506B1 (en) * 2009-10-30 2019-04-10 Janssen Biotech, Inc. Il-17a antagonists
KR20130009760A (en) * 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Cd20 antibodies and uses thereof
US9175086B2 (en) * 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
GB201011771D0 (en) * 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
GB2495113A (en) * 2011-09-29 2013-04-03 Bioinvent Int Ab Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
EP3559049B1 (en) 2011-10-28 2025-06-11 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
BR112015027313A2 (en) 2013-04-29 2017-09-26 Teva Pharmaceuticals Australia Pty Ltd anti-cd38 antibodies and attenuated interferon alfa-2b fusions
CN105658217B (en) 2013-04-29 2021-03-19 约翰霍普金斯大学 Wound healing via autologous stem cell mobilization
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
US20170173005A1 (en) 2014-03-27 2017-06-22 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
UA119352C2 (en) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд COMBINATION OF LENALIDOMIDE OR POMALIDOMIDE AND STRUCTURES OF ANTI-CD38 ANTIBODY-ATHENED INTERPHERONE ALPHA-2B AND METHOD OF TREATMENT38
WO2015197639A1 (en) * 2014-06-23 2015-12-30 Vib Vzw Tissue-specific cell depletion with two chimeric proteins
US10544199B2 (en) 2014-10-29 2020-01-28 Teva Pharmaceuticals Australia Pty Ltd Interferon alpha 2B variants
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
JP2018528257A (en) 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーＰｅｐｔｉｎｏｖｏ Ｂｉｏｐｈａｒｍａ， ＬＬＣ Formulations for improving the efficacy of hydrophobic drugs
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
CN107375940B (en) * 2017-07-18 2020-11-03 福州大学 Preparation and application of nano-medicament with adhesion factor ICAM-1 as target spot
KR102711074B1 (en) * 2021-10-26 2024-10-04 재단법인 아산사회복지재단 Antibodies derived from cancer survivors and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053360A1 (en) * 1998-08-28 2001-12-20 Genelabs Technologies, Inc. Selective apoptosis of neoplastic cells by an HLA-DR specific monoconal antibody

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ZA883159B (en) * 1987-05-04 1990-01-31 Dana Farber Cancer Inst Inc Intercellular adhesion molecules and their binding ligands
DE3852374T2 (en) 1987-11-02 1995-05-04 Baylor College Medicine Use of ICAM-1 or its functional derivatives for the treatment of non-specific inflammation.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ES2035668T3 (en) 1989-03-09 1993-04-16 Boehringer Ingelheim Pharmaceuticals Inc. USE OF INTERCELLULAR ADHERENCE MOLECULES AND THEIR UNION LINKS IN THE TREATMENT OF ASTHMA.
US5643872A (en) 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US6008058A (en) 1993-06-18 1999-12-28 University Of Louisville Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis
US5695760A (en) * 1995-04-24 1997-12-09 Boehringer Inglehiem Pharmaceuticals, Inc. Modified anti-ICAM-1 antibodies and their use in the treatment of inflammation
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20030035798A1 (en) * 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
GB2392723B (en) 2002-09-04 2005-01-12 Bioinvent Int Ab Screening methods
EP1671129A1 (en) 2003-07-21 2006-06-21 Angiogenetics Sweden AB Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway
US20060264380A1 (en) 2003-07-21 2006-11-23 Mats Hellstrom Compounds and Methods for Promoting Angiogenesis
WO2005058251A2 (en) * 2003-12-15 2005-06-30 Dendreon Corporation Hla-dr-specific antibodies, compositions and methods
WO2005086568A2 (en) * 2004-01-26 2005-09-22 Morphosys Ag Anti-icam-1 human antibodies and uses thereof
GB0525214D0 (en) * 2005-12-12 2006-01-18 Bioinvent Int Ab Biological materials and uses thereof
JP4719930B2 (en) 2008-02-29 2011-07-06 国立大学法人信州大学 Drug transport agent for detection of metastatic cancer cells in sentinel lymph node
GB0903151D0 (en) 2009-02-25 2009-04-08 Bioinvent Int Ab Antibody uses and methods
GB201011771D0 (en) 2010-07-13 2010-08-25 Bioinvent Int Ab Biological material and particular uses thereof
GB2495113A (en) 2011-09-29 2013-04-03 Bioinvent Int Ab Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
GB201300346D0 (en) 2013-01-09 2013-02-20 Biolnvent Internat Ab BiologIcal materials and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010053360A1 (en) * 1998-08-28 2001-12-20 Genelabs Technologies, Inc. Selective apoptosis of neoplastic cells by an HLA-DR specific monoconal antibody

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
BUDAGYAN V M ET AL: "Anti-ICAM-1 mAb inhibits apoptosis of thymocytes induced by human thymic stromal cells (HTSC) line", TISSUE ANTIGENS, vol. 48, no. 4-2, 1996, & 6TH INTERNATIONAL WORKSHOP AND CONFERENCE ON HUMAN LEUKOCYTE DIFFERENTIATION ANTIGENS; KOBE, JAPAN; NOVEMBER 10-14, 1996, pages 359, XP009083145, ISSN: 0001-2815 *
COLEMAN ELAINE J ET AL: "The Fc portion of UV3, an anti-CD54 monoclonal antibody, is critical for its antitumor activity in SCID mice with human multiple myeloma or lymphoma cell lines.", JOURNAL OF IMMUNOTHERAPY (HAGERSTOWN, MD. : 1997) 2006 SEP-OCT, vol. 29, no. 5, September 2006 (2006-09-01), pages 489 - 498, XP009083509, ISSN: 1524-9557 *
DOYLE IRIS S ET AL: "Specific blockade by CD54 and MHC II of CD40-mediated signaling for B cell proliferation and survival", EXPERIMENTAL CELL RESEARCH, vol. 265, no. 2, 1 May 2001 (2001-05-01), pages 312 - 318, XP002432678, ISSN: 0014-4827 *
FRANSSON JOHAN ET AL: "Rapid induction of apoptosis in B-cell lymphoma by functionally isolated human antibodies", INTERNATIONAL JOURNAL OF CANCER, vol. 119, no. 2, July 2006 (2006-07-01), pages 349 - 358, XP002432679, ISSN: 0020-7136 *
NAGY ZOLTAN A ET AL: "Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells", NATURE MEDICINE, vol. 8, no. 8, August 2002 (2002-08-01), pages 801 - 807, XP002432676, ISSN: 1078-8956 *
NIEDA M ET AL: "Dendritic cells rapidly undergo apoptosis in vitro following culture with activated CD4+ Valpha24 natural killer T cells expressing CD40L", IMMUNOLOGY, BLACKWELL PUBLISHING, OXFORD, GB, vol. 102, no. 2, February 2001 (2001-02-01), pages 137 - 145, XP002364637, ISSN: 0019-2805 *
SMALLSHAW JOAN E ET AL: "The generation and anti-myeloma activity of a chimeric anti-CD54 antibody, cUV3", JOURNAL OF IMMUNOTHERAPY, vol. 27, no. 6, November 2004 (2004-11-01), pages 419 - 424, XP009083506, ISSN: 1524-9557 *
VIDOVIC D ET AL: "SELECTIVE APOPTOSIS OF NEOPLASTIC CELLS BY THE HLA-DR-SPECIFIC MONOCLONAL ANTIBODY", CANCER LETTERS, NEW YORK, NY, US, vol. 128, no. 2, 19 June 1998 (1998-06-19), pages 127 - 135, XP000857331, ISSN: 0304-3835 *
WANG SHIXUAN ET AL: "Effect of an anti-cd54 (ICAM-1) monoclonal antibody (UV3) on the growth of human uveal melanoma cells transplanted heterotopically and orthotopically in SCID mice", INTERNATIONAL JOURNAL OF CANCER, vol. 118, no. 4, February 2006 (2006-02-01), pages 932 - 941, XP002432680, ISSN: 0020-7136 *
YOSHIDA AYAKO ET AL: "Activated monocytes induce human retinal pigment epithelial cell apoptosis through caspase-3 activation.", LABORATORY INVESTIGATION, vol. 83, no. 8, August 2003 (2003-08-01), pages 1117 - 1129, XP002432677, ISSN: 0023-6837 *
ZEN KATSUHIRO ET AL: "Monocyte-derived macrophages prime peripheral T cells of undergo apoptosis by cell-cell contact via ICAM-1/LFA-1-dependent mechanism", IMMUNOBIOLOGY, vol. 195, no. 3, 1996, pages 323 - 333, XP009083416, ISSN: 0171-2985 *

Also Published As

Publication number Publication date
JP2016039824A (en) 2016-03-24
NZ569038A (en) 2011-11-25
US20140314793A1 (en) 2014-10-23
KR20140031402A (en) 2014-03-12
US20110262461A1 (en) 2011-10-27
IL191868A0 (en) 2008-12-29
GB0525214D0 (en) 2006-01-18
IL191868A (en) 2016-12-29
ZA200804864B (en) 2009-09-30
CA2632983C (en) 2016-11-22
HUE028363T2 (en) 2016-12-28
CN101360760A (en) 2009-02-04
HK1121767A1 (en) 2009-04-30
RU2432363C2 (en) 2011-10-27
EP1960432B1 (en) 2016-04-06
KR20080090393A (en) 2008-10-08
RU2008128471A (en) 2010-01-20
DK1960432T3 (en) 2016-06-20
EP2468775A1 (en) 2012-06-27
JP2013005815A (en) 2013-01-10
CA2632983A1 (en) 2007-06-21
PT1960432T (en) 2016-07-07
PL1960432T3 (en) 2016-10-31
RU2432363C9 (en) 2014-04-27
US8758749B2 (en) 2014-06-24
EP1960432A2 (en) 2008-08-27
US20090087427A1 (en) 2009-04-02
JP2009518052A (en) 2009-05-07
UA100664C2 (en) 2013-01-25
CN102517252A (en) 2012-06-27
AU2006326267B2 (en) 2012-07-05
US7943744B2 (en) 2011-05-17
BRPI0619741A2 (en) 2011-10-11
NZ595644A (en) 2013-02-22
CN101360760B (en) 2012-07-04
KR20150023914A (en) 2015-03-05
ES2577290T3 (en) 2016-07-14
KR101446508B1 (en) 2014-10-16
NO20082524L (en) 2008-09-09
JP5247463B2 (en) 2013-07-24
AU2006326267A1 (en) 2007-06-21
SI1960432T1 (en) 2016-08-31
NO341192B1 (en) 2017-09-11
MY147438A (en) 2012-12-14
US9803013B2 (en) 2017-10-31
WO2007068485A2 (en) 2007-06-21

Similar Documents

Publication Publication Date Title
WO2007068485A3 (en) Biological materials and uses thereof
NZ592432A (en) Antibodies that specifically block the biological activity of a tumor antigen Kidney associated antigen 1 (KAAG1)
CY1121208T1 (en) NATALIZUMAB ANTIBODIES
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2005113601A8 (en) Antibodies and molecules derived therefrom that bind to steap-1 proteins
IL204157A (en) Isolated antibodies or antigen binding fragments that bind to human 5b6 protein on the surface of a dendritic cell, compositions comprising them and their uses
WO2006084264A3 (en) Cd20 antibody variants and uses thereof
ME01810B (en) Neutralising antibody molecules having specificity for human il-17
WO2008055080A3 (en) Method for blocking non-specific protein binding on a functionalized surface
WO2009063965A1 (en) Monoclonal antibody capable of binding to anexelekto, and use thereof
ZA200907385B (en) Binding proteins, including antibodies, antibody derivative and antibody fragments, that specifically bind cd154 and uses thereof
WO2007109370A3 (en) Methods for identifying polypeptide targets and uses thereof for treating immunological diseases
IL186385A0 (en) Antibodies and molecules derived therefrom that bind to 161p2f10b proteins
ZA200804594B (en) Antibody molecules having specificity for human IL-6
WO2008099178A3 (en) Binding members for ige molecules
WO2008098917A3 (en) Novel antibodies against igf-ir
WO2008019326A3 (en) Ephb3-specific antibody and uses thereof
WO2009120183A3 (en) System for the detection of a biological pathogen and use thereof
AU2006239318A8 (en) Cancer specific PCNA isoform binding antibodies and uses thereof
WO2007026972A3 (en) Binding protein molecule
WO2005033145A8 (en) Antibodies to nik, their preparation and use
ZA200709303B (en) Antibodies and related molecules that bind to 161P2F210B proteins
WO2007144619A3 (en) Antibodies selectively binding aggregated prion protein 106-126 and uses thereof
WO2006116319A3 (en) Reagents that bind ccx-ckr2

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006829616

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12008501338

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 4866/DELNP/2008

Country of ref document: IN

Ref document number: 2006326267

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008060967

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: 2632983

Country of ref document: CA

Ref document number: 569038

Country of ref document: NZ

Ref document number: 2008544879

Country of ref document: JP

Ref document number: 1020087014064

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/007717

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2006326267

Country of ref document: AU

Date of ref document: 20061208

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2006326267

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2008128471

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 200680051213.0

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2006829616

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12097193

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0619741

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080612

WWE Wipo information: entry into national phase

Ref document number: 1020147003908

Country of ref document: KR